8 research outputs found
Insulin-like growth factor 1 receptor polymorphism rs2229765 and circulating interleukin-6 level affect male longevity in a population-based prospective study (Treviso Longeva--TRELONG).
Insulin-like growth factor 1 (IGF-1) signaling modulation has been associated with increased lifespan in model organisms, while high levels of circulating interleukin-6 (IL-6) are a marker of disability and mortality. In the prospective, population-based "Treviso Longeva"--TRELONG Study from Italy (n = 668, age range 70-105.5 years at baseline, followed for seven years) we investigated the effects of survival on the IGF-1 receptor (IGF-1R) gene polymorphism rs2229765, the IL-6 gene promoter polymorphism rs1800795, and plasma concentrations of IGF-1 and IL-6, alone or in combination. We found a sex-dependent effect for the IGF-1R rs2229765 polymorphism, as male carriers of the homozygous A/A genotype survived longer, while the IL-6 rs1800795 genotype did not influence overall or sex-specific longevity. Higher IL-6 levels were more detrimental for survival among males than females, while IGF-1 had no dose-response effect. These findings sustain the hypothesis that sex-specific longevity relies on detectable differences in genetic and biochemical parameters between males and females
Association of SORL1 Alleles with Late-Onset Alzheimer’s Disease. Findings from the GIGAS_LOAD Study and Mega-Analysis
The pathophysiology of Alzheimer’s disease (AD) is influenced by
sorting-protein related receptor (sorLa) that is less expressed in AD
patients. The gene encoding sorLa (SORL1) has been investigated as a
susceptibility factor for late-onset AD (LOAD) with conflicting results.
Our objectives were to confirm the association between SORL1 SNPs and
LOAD in two independent South-European centers and to perform a
mega-analysis of published samples. We analyzed three SORL1 SNPs (intron
6: rs668387; rs689021; rs641120) from the Greece-Italy Genetic
Association Study on late-onset AD (GIGAS_LOAD). Greek sample included
96 patients with LOAD (DSM-IV) and 120 unrelated controls. In Italy, a
community-based sample is ongoing. 47 LOAD patients and 165 controls
were recruited until study endpoint. These samples and previously
published ones (Alzgene) were pooled as in a single study. A test for
trend was used to analyze genotype association. In the GIGAS_LOAD
sample no association was detected between SORL1 genotypes and LOAD.
Conversely all SNPs were associated with LOAD in mega-analysis based on
ordinal classification of genotypes (Armitage’s test: p<0.001). Although
our analysis of pooled samples has positive results for the association
between SORL1 and AD, there is substantial heterogeneity across studies.
Thus further examination into SORL1 SNPs and the population is necessary
to determine the role of SORL1 in LOAD
Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors
We conducted a genome-wide association study in a cohort of 176 Italian Alzheimer's disease (AD) patients with extreme phenotype of response to cholinesterase inhibitors. Patients were classified into responders in case of positive, stable, or 3 points worsening during a median follow-up of 0.85 years of treatment. Forty-eight single-nucleotide polymorphisms were selected for replication in 198 additional AD-treated patients. By using the dichotomous response trait and a quantitative trait approach (change of mini-mental state examination), a nominal replication and evidence of association when combining data were achieved for 2 single-nucleotide polymorphisms associated with response to treatment: rs6720975(A) (p(combined) = 2.9 x 10(-5), beta regression coefficient: 1.61) and rs17798800(A) (p(combined) = 6.8 x 10(-6), odds ratio = 0.38, 95% confidence interval = 0.25-0.58). Rs6720975 maps in the intronic region of PRKCE, a protein kinase involved in several cellular functions, whereas rs17798800 is intergenic and, according to expression quantitative trait locus (eQTL) analysis, it acts as a cis-regulator of NBEA, an A kinase-anchoring protein playing a substantial role in the maturation of the nervous system. Despite its limitations, this project paves the way for the application of personalized medicine in AD patients and for collaborative efforts in this field. (C) 2013 Elsevier Inc. All rights reserved